Article Details

COVID-19 vaccine developer CanSinoBIO seeks to raise $743m in STAR IPO

Retrieved on: 2020-07-29 16:37:30

Tags for this article:

Click the tags to see associated articles and topics

COVID-19 vaccine developer CanSinoBIO seeks to raise $743m in STAR IPO. View article details on hiswai:

Excerpt

<div>Following the IPO, <b>Qiming Venture Partners</b> unit QM29 Limited will hold 5.26 per cent stake, Lilly Asia Ventures Fund's LAV Spring (Hong Kong) ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up